Abstract
Advances in early reperfusion therapies focused on the revascularization of the ischemic tissues, in the last decades, lead to reduced mortality in acute myocardial infarction (MI) patients. However, a large proportion of patients show inadequate myocardial perfusion because of dysfunction of the microcirculation. The high prevalence of microvascular dysfunction after reperfusion therapies and the negative prognostic of this procedure justify the search for therapeutic strategies that aim to restore the microvascular network. It is well known that the size of the initial infarct, the duration of ischemia and the efficiency of reperfusion determine myocardial tissue damage and cardiomyocyte loss after myocardial infarction. Therefore any advancement on the mechanisms that induce the repair process of microvascular dysfunction after reperfused MI is of great interest. Here, we will review the different proteins and cells known to participate in angiogenesis induction post-MI and we will also discuss the potential pharmacological and cellular processes that promote the recovery of microvasculature by angiogenesis stimulation after MI.
Keywords: Angiogenesis, reperfusion therapies, microvascular dysfunction, myocardial infarction, myocardial perfusion, ischemia.
Current Pharmaceutical Design
Title:Microvasculature Recovery by Angiogenesis After Myocardial Infarction
Volume: 24 Issue: 25
Author(s): Lina Badimon and Maria Borrell*
Affiliation:
- CIBER-CV, Instituto de Salud Carlos III, Madrid,Spain
Keywords: Angiogenesis, reperfusion therapies, microvascular dysfunction, myocardial infarction, myocardial perfusion, ischemia.
Abstract: Advances in early reperfusion therapies focused on the revascularization of the ischemic tissues, in the last decades, lead to reduced mortality in acute myocardial infarction (MI) patients. However, a large proportion of patients show inadequate myocardial perfusion because of dysfunction of the microcirculation. The high prevalence of microvascular dysfunction after reperfusion therapies and the negative prognostic of this procedure justify the search for therapeutic strategies that aim to restore the microvascular network. It is well known that the size of the initial infarct, the duration of ischemia and the efficiency of reperfusion determine myocardial tissue damage and cardiomyocyte loss after myocardial infarction. Therefore any advancement on the mechanisms that induce the repair process of microvascular dysfunction after reperfused MI is of great interest. Here, we will review the different proteins and cells known to participate in angiogenesis induction post-MI and we will also discuss the potential pharmacological and cellular processes that promote the recovery of microvasculature by angiogenesis stimulation after MI.
Export Options
About this article
Cite this article as:
Badimon Lina and Borrell Maria *, Microvasculature Recovery by Angiogenesis After Myocardial Infarction, Current Pharmaceutical Design 2018; 24 (25) . https://dx.doi.org/10.2174/1381612824666180629162726
DOI https://dx.doi.org/10.2174/1381612824666180629162726 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetic Polymorphisms of Type-1 and Type-2 Inflammatory Cytokines in Ischaemic Stroke
Vascular Disease Prevention (Discontinued) A Review of Natural and Synthetic Antioxidants Important for Health and Longevity
Current Medicinal Chemistry Current and Experimental Antibody-Based Therapeutics: Insights, Breakthroughs, Setbacks and Future Directions
Current Molecular Medicine Application of Proteomics in Cardiovascular Research
Current Proteomics Gene Therapy in Lung Transplantation
Current Gene Therapy Efficacy and Cardiovascular Safety of DPP-4 Inhibitors
Current Drug Safety Neuroprotective Effects of a Glutathione Depletor in Rat Post-Ischemic Reperfusion Brain Damage
CNS & Neurological Disorders - Drug Targets Cardioprotective Effect of Resveratrol and Resveratroloside
Cardiovascular & Hematological Agents in Medicinal Chemistry Anti-Inflammatory and Anti-Apoptotic Effects of Levosimendan in Decompensated Heart Failure: A Novel Mechanism of Drug-Induced Improvement in Contractile Performance of the Failing Heart
Current Medicinal Chemistry - Cardiovascular & Hematological Agents The Medicinal Chemistry of Nitrite as a Source of Nitric Oxide Signaling
Current Topics in Medicinal Chemistry Impact of Sex Hormone Metabolism on the Vascular Effects of Menopausal Hormone Therapy in Cardiovascular Disease
Current Drug Metabolism A Novel Systemic Indicator of Periodontal Tissue Damage: Ischemia Modified Albumin
Combinatorial Chemistry & High Throughput Screening Repetitive Transient Phosphodiesterase-3 Inhibition Eliminates Non-ischemic Cardiac Remodeling and Failure
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Adipose-Derived Stromal/Stem Cells (ASC) in Regenerative Medicine: Pharmaceutical Applications
Current Pharmaceutical Design Pro- and Anti-Arrhythmic Effects of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Telomere/Telomerase System: A New Target of Statins Pleiotropic Effect?
Current Vascular Pharmacology Mechanisms of Neuronal Damage and Neuroprotection Underlying Ischemia/Reperfusion Injury after Physical Exercise
Current Drug Targets TRP Channels in Respiratory Pathophysiology: the Role of Oxidative, Chemical Irritant and Temperature Stimuli
Current Neuropharmacology “PARG Inhibitors’ Success: A Long Way to Go!”
Current Enzyme Inhibition Erratum
Current Medicinal Chemistry